Prognostic Factors and Postoperative Survival in Clear Cell Renal Carcinomas. A Histopathological Diagnosis

2021 ◽  
pp. 8-17
Author(s):  
P. Colaci ◽  
A. L. Errecalde ◽  
A. M. Inda ◽  
M. Garcia
Keyword(s):  
Prognostic Factors ◽  
Clear Cell ◽  
Postoperative Survival ◽  
Histopathological Diagnosis

scholarly journals Is clear cell sarcoma a malignant form of psammomatous melanotic schwannoma?

2006 ◽  
Vol 21 (6) ◽  
pp. 1-4 ◽  
Author(s):  
Ahmet Şengöz ◽  
Erol Taşdemiroğlu ◽  
Halit Togay
Keyword(s):  
Malignant Melanoma ◽  
Nerve Root ◽  
Clear Cell ◽  
Clear Cell Sarcoma ◽  
Histopathological Diagnosis ◽  
Total Resection ◽  
Cell Sarcoma ◽  
Melanotic Schwannoma ◽  
Psammomatous Melanotic Schwannoma

✓The authors present a case of clear cell sarcoma (CCS) in which the tumor originated in the S-1 nerve root and had been previously diagnosed as psammomatous melanotic schwannoma (PMS). This is the third case of a spinal nerve root origin for CCS reported in the English-language literature. The similar histogenesis of CCS and malignant melanoma supports the hypothesis that biological agents or immunotherapy are potentially important areas of investigation. The patient underwent S1–3 laminectomy and gross-total resection of the mass lesion. The border of the resection was extended 1 cm distal to the tumor margin. The postoperative period was uneventful. The new histopathological diagnosis was CCS (malignant melanoma of soft tissue). Despite total resection, the patient returned with disseminated disease at the 18-month follow-up visit. His follow-up magnetic resonance image of the lumbar spine revealed sacral L5–S3 involvement of the vertebral bodies along with disseminated cauda equina seeding. A CCS originating from peripheral nerves is quite rare. The histopathological and immunohistochemical appearance of CCSs resembles those of PMSs. Surgery should be the first choice of treatment.

Demographic, Clinical, and Prognostic Factors of Ovarian Clear Cell Adenocarcinomas According to Endometriosis Status

2017 ◽  
Vol 27 (9) ◽  
pp. 1804-1812 ◽  
Author(s):  
Tine H. Schnack ◽  
Estrid Høgdall ◽  
Lotte Nedergaard Thomsen ◽  
Claus Høgdall
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Cox Regression ◽  
Clear Cell ◽  
Statistical Tests ◽  
Gynecological Cancer ◽  
Population Based ◽  
Clear Cell Adenocarcinoma ◽  
Ovarian Endometriosis ◽  
Increased Risk

ObjectivesWomen with endometriosis carry an increased risk for ovarian clear cell adenocarcinomas (CCCs). Clear cell adenocarcinoma may develop from endometriosis lesions. Few studies have compared clinical and prognostic factors and overall survival in patients diagnosed as having CCC according to endometriosis status.MethodsPopulation-based prospectively collected data on CCC with coexisting pelvic (including ovarian; n = 80) and ovarian (n = 46) endometriosis or without endometriosis (n = 95) were obtained through the Danish Gynecological Cancer Database. χ2 Test, independent-samples t test, logistic regression, Kaplan-Meier test, and Cox regression were used. Statistical tests were 2 sided. P values less than 0.05 were considered statistically significant.ResultsPatients with CCC and pelvic or ovarian endometriosis were significantly younger than CCC patients without endometriosis, and a higher proportion of them were nulliparous (28% and 31% vs 17% (P = 0.07 and P = 0.09). Accordingly, a significantly higher proportion of women without endometriosis had given birth to more than 1 child. Interestingly, a significantly higher proportion of patients with ovarian endometriosis had pure CCCs (97.8% vs 82.1%; P = 0.001) as compared with patients without endometriosis. Overall survival was poorer among CCC patients with concomitant ovarian endometriosis (hazard ratio, 2.56 [95% confidence interval, 1.29–5.02], in the multivariate analysis.ConclusionsAge at CCC diagnosis and parity as well as histology differ between CCC patients with and without concomitant endometriosis. Furthermore, CCC patients with concomitant ovarian endometriosis have a poorer prognosis compared with endometriosis-negative CCC patients. These differences warrant further research to determine whether CCCs with and without concomitant endometriosis develop through distinct pathogenic pathways.

Venous and nerve invasion as prognostic factors in postoperative survival of patients with resectable cancer of the rectum

1983 ◽  
Vol 26 (9) ◽  
pp. 613-617 ◽  
Author(s):  
J. B. Knudsen ◽  
Tove Nilsson ◽  
M. Sprechler ◽  
Å. Johansen ◽  
N. Christensen
Keyword(s):  
Prognostic Factors ◽  
Postoperative Survival ◽  
Cancer Of The Rectum ◽  
Nerve Invasion ◽  
Resectable Cancer

Clinical prognostic factors associated with outcome in patients with metastatic clear-cell renal cell cancer treated with everolimus.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 443-443
Author(s):  
Robert J. Amato ◽  
Amber Flaherty ◽  
Somyata Saxena ◽  
Mika Stepankiw
Keyword(s):  
Prognostic Factors ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Clear Cell ◽  
Left Kidney ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Factors Associated ◽  
Kidney Involvement ◽  
Clear Cell Rcc

443 Background: Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has demonstrated efficacy affects tumor growth by blocking growth factor stimulation, arresting cell cycle progression, and inhibiting angiogenesis. mTOR inhibitors and agents with primarily antiangiogenic activity have been shown to have efficacy in renal cell cancer (RCC). This study expanded the original everolimus study of 41 patients with metastatic clear cell renal cell cancer to 66 patients to examine outcome and clinical prognostic factors associated with outcome Methods: Patients had confirmed predominantly clear cell RCC. Everolimus was given at a dose of 10 mg daily orally without interruption (28-day cycle), with dose modifications for toxicity (graded according to National Cancer Institute Common Toxicity Criteria, version 3.0). Patients were evaluated every 2 cycles (8 weeks) using Response Evaluation Criteria in Solid Tumors (RECIST). Results: Of 66 evaluable and treated patients, 73% were male, and 45% were >60. Forty-five percent had right kidney involvement, 49% left kidney involvement, and 6% had dual kidney involvement. Eighty-six percent had prior systemic therapy, and 76% of patients had at least two metastatic sites including lung (72%), liver (26%), bone (48%), lymph nodes (50%), adrenal (21%), and other (39%). Twenty-four (36%) of patients had a progression-free survival (PFS) of ≥12 months, and 40 patients (61%) had an overall survival (OS) ≥12 months. Factors most likely to have an influence on OS benefit was high LDH, alkaline phosphatase, and calcium; low hemoglobin; and prior treatment with tyrokinase inhibitors. Conclusions: Everolimus was found to have clinical benefit in patients with clear cell RCC. Clinical prognostic factors may help determine patients most likely to receive benefit from everolimus. Information regarding curves and correlation between prognostic factors and OS and PFS will be presented.

An evaluation of survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: A Gynecologic Oncology Group experience.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 5534-5534 ◽  
Author(s):  
John H. Farley ◽  
William E. Brady ◽  
Michael J. Birrer ◽  
David Marc Gershenson ◽  
Gini F. Fleming ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Prognostic Factors ◽  
Epithelial Ovarian Cancer ◽  
Cell Carcinoma ◽  
Treatment Effect ◽  
Late Stage ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Early Stage ◽  
Performance Status

5534 Background: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods: Data from stage I-IV epithelial ovarian cancer (EOC) patients who participated in 12 randomized GOG protocols using platinum-based chemotherapy were reviewed. Proportional hazards models adjusted for age and stratified by protocol, treatment arm, stage, performance status (PS), and race were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). Results: There were 10,803 patients enrolled, 1272 were not eligible: leaving 9,531, of whom 544 (6%) had OCCC, 7,054 (74%) had SOC, and 1,933 (20%) had other; only the OCCC and SOC are considered here. OCCC were significantly younger, more often of Asian race, stage I, good PS, and optimally surgically debulked than SOC patients. Prior to adjustment, OCCC had better PFS and OS due to better prognostic factors. There was no significant difference in PFS or OS for early stage OCCC patients compared to high-grade (HG) SOC patients. For late stage patients, OCCC had poorer PFS and OS compared to SOC, OS HR= 1.66 (1.43, 1.91; p < 0.001). For both optimal, HR = 1.34 (1.10, 1.63; p = 0.003) and suboptimal, HR = 3.18 (2.13, 4.75; p < 0.001) OCCC had a significantly poorer OS than SOC. After adjusting for age and stratified by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR= 1.53 (1.33,1.76; p < 0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly taxol versus observation in SOC compared to OCCC (p = 0.048). Conclusions: This is one of the largest analyses to date of OCCC treated in a uniform manner . OCCC patients have better PFS and OS compared to SOC; this, is due to their better prognostic factors. There was no observed difference in PFS or OS for early stage OCCC versus HGSOC. In late-stage patients, OCCC was significantly associated with decreased OS which was true for both optimal and suboptimally debulked patients. Finally, treatment effect was influenced by histology.

scholarly journals Cytoplasmic PAR-3 protein expression is associated with adverse prognostic factors in clear cell renal cell carcinoma and independently impacts survival

2014 ◽  
Vol 45 (8) ◽  
pp. 1639-1646 ◽  
Author(s):  
Julien Dagher ◽  
Frédéric Dugay ◽  
Nathalie Rioux-Leclercq ◽  
Gregory Verhoest ◽  
Emmanuel Oger ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factors ◽  
Protein Expression ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma

scholarly journals Histopathological spectrum of lesions in nephrectomy specimens: Five years’ experience in a private lab.

2021 ◽  
Vol 28 (12) ◽  
pp. 1824-1828
Author(s):  
Shireen Hamid ◽  
Shazia Aslam ◽  
Hafiza Azka Iqbal ◽  
Hafsa Tariq ◽  
Rafique Cheema ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Malignant Tumor ◽  
Clear Cell ◽  
Renal Diseases ◽  
Histopathological Diagnosis ◽  
Age Group ◽  
Cell Renal Cell Carcinoma ◽  
Neoplastic Lesion ◽  
Time Period ◽  
Study Setting

Objective: The aim of this study was to evaluate the histopathological changes in the nephrectomy specimens. Study Design: Retrospective study. Setting: Private Lab, Located in Faisalabad. Period: January 2015 to December 2019. Material & Methods: A total of 113 cases were included in the study. In this study paraffin blocks and previous slides along with clinical data were analyzed according to standard protocols. Patient age, sex and histological diagnosis were noted and compared. Results: In this study we analyzed 113 cases, received during a five year time period. Out of which 60 (53%) were males and 53 (47%) were females. Most common age group ranges from 51 to 60 years and the least common affected group was 71 to 80 years. The neoplastic cases were 66 (58%) and nonneoplastic cases were 47(42%). Neoplastic were further sub- divided in to 3(5%) benign cases and 63(95%) malignant cases.  Most common neoplastic lesion was clear cell renal cell carcinoma, 49 (74%) cases and most common non- neoplastic condition was chronic pyelonephritis, 37 (78%) cases. Conclusion: Nephrectomy is the ultimate surgical procedure for the treatment of renal diseases. The 5th to 6th decade is the most common age group of patients affected by non- neoplastic conditions leading to non-functioning kidney. Malignant tumor like clear cell carcinoma is the most common malignant tumor in our society. Early clinical, radiological and histopathological diagnosis of renal diseases will help out patients for proper management. Thus every nephrectomy specimen should be evaluated through clinico –pathological correlation.

Sign in / Sign up

Export Citation Format

Share Document